IFNA1 and myeloid sarcoma: Additionally, differentially methylated regions located in the RSAD2, MX1, IFI44L and PLSCR1 genes, which are upregulated in the blood cells of IFN-treated MS patients, thus indicating biomarkers for monitoring the effects of IFN treatment in PBMCs (Souren et al., 2019).